The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 per cent in women with type-2 diabetes, a new University of Sydney study reveals.
"The finding is good news for women," says the study's chairman, University of Sydney Professor, Tony Keech.
"The study shows that fenofibrate reduced the risk of dying from cardiovascular disease, or having a stroke or other adverse cardiovascular event by 30 per cent in women and 13 per cent in men."